SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Epigral informs about press release

27 Jan 2025 Evaluate
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Epigral has informed that it enclosed a Press Release for Un-Audited Financial Results - Q3 FY2025. The said Press Release is also available at www.epigral.com in the Investor Relations section.

The above information is a part of company’s filings submitted to BSE.


Epigral Share Price

1190.30 21.00 (1.80%)
22-Apr-2026 14:40 View Price Chart
Peers
Company Name CMP
BASF India 3760.00
Tata Chemicals 709.00
SRF 2495.50
Pidilite Inds. 1418.45
Deepak Nitrite 1750.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×